Repare bags $40m from Roche as solid tumour trial begins
Phase 2License out/inPhase 1Clinical Result
Preview
Source: Pharmaceutical Technology
Repare is eligible to up to $1.2bn from Roche. Credit: Bonsales via Shutterstock.
Repare Therapeutics announced the receipt of a $40m milestone payment from Roche following the dosing of its first patient in a Phase II clinical trial investigating camonsertib in solid tumours.
Camonsertibis a precision oncology drug treating cancer by targeting specific genetic alterations in solid tumours. The drug works by inhibiting ataxia telangiectasia and rad3-related protein (ATR), involved in DNA repair and cell cycle regulation.
Repare received an upfront payment of $125m when the collaboration was announced in July 2022, and is eligible to receive up to $1.2bn on achieving clinical, regulatory and sales milestones. Under the terms of the collaboration, Repare has the option to opt-in for a 50/50 co-development and profit-sharing arrangement in the US market.
The Phase II TAPISTRY study (NCT04589845) is an open-label, multi-centre trial evaluating the safety and efficacy of camonsertnib in patients with unresectable, locally advanced, or metastatic solid tumours. The eventual 920-patient cohort will receive treatment according to their specific tumour characteristics and genomic alterations.
Camonsertnib is also being investigated in several other clinical trials. The Phase Ib/II MORPHEUS trial (NCT03337698), evaluating the safety and efficacy of the drug in patients with metastatic non-small cell lung cancer (NSCLC), enrolled the first patient in the camonsertnib-arm in October.
Repare announced data from the Phase I/II TRESR and Ib/II ATTACC trials last year. ATTACC, in collaboration with Roche, is evaluating camonsertib plus two PARPis, niraparib or olaparib, to treat patients with advanced solid tumours, while TRESR is assessing camonsertib in combination with talazoparib poly (ADP-ribose) polymerase inhibitor (PARPi). The overall clinical benefit rate (CBR) for all patients was 48%.
In the announcement accompanying the milestone, Repare’s CEO Lloyd Segal said: “This milestone is a key achievement for us, demonstrating Roche’s commitment to the global clinical development of camonsertib and highlighting their exploration of development opportunities for camonsertib across multiple tumour types and genetic alterations to maximize patient impact.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.